Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 20/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123864 | 1.00 | ESR1 (0.79) | ESR1CYP3A4KCNH2 | |
| SCHEMBL25002290 | 1.00 | ESR1 (0.79) | ESR1CYP3A4KCNH2 | |
| SCHEMBL30123773 | 0.97 | ESR1 (0.78) | ESR1 | |
| SCHEMBL17839193 | 0.97 | ESR1 (0.78) | ESR1 | |
| SCHEMBL17839580 | 0.92 | ESR1 (0.76) | ESR1KCNH2 | |
| SCHEMBL21725032 | 0.92 | ESR1 (0.76) | ESR1KCNH2 | |
| SCHEMBL30123889 | 0.92 | ESR1 (0.76) | ESR1KCNH2 | |
| SCHEMBL17839179 | 0.89 | ESR1 (0.79) | ESR1 | |
| SCHEMBL30123563 | 0.89 | ESR1 (0.79) | ESR1 | |
| SCHEMBL31412777 | 0.88 | ESR1 (1.00) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760623-B1 | TETRAHYDRO-PYRIDO[3,4-B]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-03-18 | — | — | EP | claimed |
| EP-3760623-A1 | TETRAHYDRO-PYRIDO[3,4-B]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | claimed |
| EP-3760623-B1 | TETRAHYDRO-PYRIDO[3,4-B]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-11676731-B2 | Diagnostic and therapeutic methods for the treatment of breast cancer | GENENTECH, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230045776-A9 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230045776-A9 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20220044819-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR THE TREATMENT OF BREAST CANCER | GENENTECH, INC. | 2022-02-10 | — | — | US | disclosed |
| CN-113490850-A | Diagnostic and therapeutic methods for treating breast cancer | F·霍夫曼-拉罗氏股份公司 | 2021-10-08 | — | — | CN | disclosed |
| US-20210236473-A1 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210236473-A1 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-11081236-B2 | Diagnostic and therapeutic methods for the treatment of breast cancer | GENENTECH, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200082944-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR THE TREATMENT OF BREAST CANCER | GENENTECH, INC. | 2020-03-12 | — | — | US | disclosed |
| US-20180235945-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2018-08-23 | — | — | US | disclosed |
| US-9980947-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980947-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980947-B2 | Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20160175289-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| WO-2016097072-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| US-20160175289-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160175289-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236473-A1 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | ESR1 3/4885CYP3A4 162/4885KCNH2 4144/4885 |
| US-20160175289-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | ESR1 3/4885CYP3A4 162/4885KCNH2 4144/4885 |
| US-20180235945-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | ESR1 3/4885CYP3A4 162/4885KCNH2 4144/4885 |
| US-20230045776-A9 | TETRAHYDRO- PYRIDO[3,4- b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | ESR1 3/4885CYP3A4 162/4885KCNH2 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.